Researchers found that CTX-1301 delivered consistent tri-modal release of the dexmethylphenidate hydrochloride
(d-MPH), and extended d-MPH blood plasma levels by 4 hours when compared to Focalin XR's bi-phasic release of d-MPH.
M2 EQUITYBITES-September 27, 2017-Lannett awarded US FDA approval for Dexmethylphenidate Hydrochloride
Tablets in 2.5 mg, 5 mg & 10 mg
Food and Drug Administration ("FDA") approval on its Abbreviated New Drug Application ("ANDA") for a generic version of Focalin XR (dexmethylphenidate hydrochloride
) extended-release capsules CII, 25 and 35 mg.
Pharmaceutical company Intellipharmaceutics International (TSX:I) said on Thursday that Teva Pharmaceuticals has launched the generic version of the 5mg strength of its dexmethylphenidate hydrochloride
generic of Focalin XR(R).
Reddy's Delayed-ReleaseTablets, 375 mg/20 mg (base), 500 mg/20 mg (base) Norethindrone and Ethinyl Estradiol Tablets Famy Care USP, 1 mg/0.05 mg Gatifloxacin Ophthalmic Solution, 0.5% Lupin Dexmethylphenidate Hydrochloride
Mylan Extended-Release Capsules, 30 mg Adefovir Dipivoxil Tablets, 10 mg Sigmapharm Adenosine Injection USP, 3 mg/ml, Teva packaged in 60 mg/20 ml and 90 mg/30 ml single-dose vials Lansoprazole Delayed-Release Capsules Teva USP, Amoxicillin Capsules USP and Clarithromycin Tablets USP, 30 mg/500 mg/500 mg Doxercalciferol Injection, 2 mcg/mi, Innopharma pack-aged in 4 mcg/2 ml single-use ampules SEPTEMBER 2013 Bivalrudin for Injection, 250 mg/vial, Hospira packaged in single-use flip-top vials Azacitidine for Injection, 100 mg, packaged Dr.
* Focalin, Focalin XR (dexmethylphenidate hydrochloride
The litigation involved a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR(R) (dexmethylphenidate hydrochloride
"Open-Label Study of Dexmethylphenidate Hydrochloride
in Children and Adolescents with Attention Deficit Hyperactivity Disorder".
The patch provides children with ADHD consistent release of dexmethylphenidate hydrochloride
throughout the day.
- US-based clinical stage biopharmaceutical company Cingulate Therapeutics, LLC has presented a poster titled, "Development and In Vivo Pharmacoscintigraphic Evaluation of a Novel Triple-Release Dexmethylphenidate Hydrochloride
Tablet for Improved Once Daily Dosing" at the American Association of Pharmaceutical Scientists annual meeting held in San Diego, CA, the company said.
The company said the Focalin XR (Dexmethylphenidate hydrochloride
) extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged six years and older.